Reply
Our article was intended to quantify the impact of the quality of mammographic screening on breast cancer mortality reduction, unfavourable side effects such as biopsies and referrals, and cost.' We showed, with the aid of three plausible scenarios, that the breast cancer mortality reduction achieved at population level might well vary between 10-12% (difference of 400 deaths prevented per year) between a "low quality" and "high quality" scenario, and a cost effectiveness ratio between 15 000 and 21 000 DM per life-year gained in a German situation. We did not state or suggest that screening in the decentralised health care system in Germany may not be worth implementing. Given the disease and the possibilities of mammography when screening a large proportion of thus far unsymptomatic women, breast screening might still be considered cost effective even in a low quality scenario. It should not, however, be the goal for a national programme, and our analysis simply shows that quality improvement is necessary and cost effective; it is not ethically acceptable not to put much effort into it for the women involved. Robust evidence is something we are all aiming at. The lack of empirical data in the German setting is clearly stressed throughout our article, and explained for all important aspects and conclusions in the discussion (incidence data, stage distribution, interval cancers). It is the first, and indeed so far the only, cost effectiveness analysis of mammographic screening in Germany. It can only be based on whatever data are presently available. It uses several sources and a well defined model to supplement other data in a consistent way. We have been explicit about this, and the model has been used and cross checked in several contexts. One relatively hard piece of evidence is the incidence and mortality data from Germany, which led us to assume a worse survival rate in Germany compared with The Netherlands. Up to the beginning of the 90s, neither these data nor those from the KFU programme showed that screening had had a substantial effect, but apparently the Medical Tribune did show this in 1996. Even Dr Werneke can only state that the clinical stage distribution probably differs. The working of the present "wild screening" in Germany has never been analysed in a rigorous manner. Annual reports on the German screening programme do not give data on these activities. Cancer registries, where they exist, can not often give valid information on the mode of detection. First results from four different regions in Germany, comprising approximately 1350 new breast cancer cases in 1995-96, show that 45% are diagnosed at stage pTl (s 2 cm).3 This corresponds very well with our estimate for the "reference situation" in Germany without a nationwide screening programme.
We are not clear about part of the message in Mrs Werneke's letter. She argues that it may not be worth implementing screening in Germany, claims rather good results from spontaneous screening (having influenced stage distribution and detection rates in an organised screening setting), but ends again with confusion, stating that the high quality scenario exemplified in The Netherlands is unlikely in Germany. Our paper is based on German mammography study results and it is true that the German mammography study may not be identical to a future national mammographic screening programme, should there be such a programme. So far, however, our data are the closest estimate ofwhat would happen and the extent to which quality would influence screening results. As far as the accusations that our approach is partly invalid and sometimes merely hypothetical are concerned, we can but refer to the reality of the Dutch nationwide screening programme and our modelling estimates made beforehand,2 and these new German data.3
With estimates from actual German data we concluded that it was likely that up to 20% of the total costs of a screening programme could be spent on quality improvement in order to achieve a substantially higher reduction in mortality while retaining the same cost effectiveness ratio. In that sense, we hope we have helped German decision makers view the reality of the German decentralised health care system, and if not, perhaps other European countries considering implementation of cancer screening programmes. 
